TAKTakedaRunning, no new patients
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.9
2 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 245 (final count)
- Started
- Oct 4, 2018
- Main results expected
- Aug 12, 2022
- Fully finished
- Jul 31, 2027
- Results posted
- Oct 27, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Minimal Residual Disease (MRD)-Negative Complete Remission (CR) at The End of Induction Phase
Measured over: From Cycle 1 through Cycle 3 (approximately 3 months) (Cycle length = 28 days)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.9, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03589326 · record last updated 2025-11-26 · checked 2026-11-09 15:47 UTC